Coronavirus disease COVID-2019
https://doi.org/10.30895/2312-7821-2020-8-1-3-8
Abstract
The paper presents data on the coronavirus diseaseCOVID-2019 caused by the SARS-CoV-2 coronavirus, which was temporarily named 2019-nCoV (2019 novel coronavirus) until 11 February 2020. An outbreak of pneumonia of unknown etiology in Wuhan (Hubei province of China) which was first described in an official publication of the Chinese Office of the World Health Organization on December 31, 2019, attracted attention of both dedicated experts and the entire international community. On January 30, 2019 it was recognised as a public health emergency of international concern. The first cases were reported on December 12, 2019 in China, and on January 31, 2020 Russia reported its first two cases of the infection in two Chinese citizens staying in Russia. The causative agent is the new SARS-CoV-2 coronavirus. It had not been detected before, and was first identified by Chinese researchers on January 7, 2020 under the temporary name 2019-nCoV. The aim of the study was to summarise information about coronavirus diseaseCOVID-2019 beginning from the onset of the epidemic until early March 2020. The paper provides general information about coronaviruses, developments of the COVID-2019 epidemic caused by the SARS-CoV-2 coronavirus, and gives an assessment of the global epidemiological situation. It cites the recommendations of national regulatory authorities and the World Health Organization on the treatment of various forms of coronavirus infection and septic shock caused by SARS-CoV-2, including target values of systemic hemodynamics, a list of recommended medicines, methods of their use, and limitations of pharmacotherapy.
Keywords
Funding: The study reported in this publication was carried out as part of a publicly funded research project No. 056-00003-20-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. AAAA-A18-118021590046-9)
About the Author
B. K. Romanov
Scientific Center for Expert Evaluation of Medical Products
Russian Federation
Russian Federation
Boris K. Romanov, Dr. Sci. (Med.), Assoc. Prof.
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
References
1. Pokrovsky VI, Kiselev OI, Nazarov PG. SARS: severe acute respiratory syndrome. New virus, new disease. Tsitokiny i vospalenie = Cytokines and Infl ammation. 2003;2(2):42–51 (In Russ.)
2. Paules CI, Marston HD, Fauci AS. Coronavirus infections— more than just the common cold. JAMA. 2020;323(8):707–8. https://doi.org/10.1001/jama.2020.0757
3. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020. [Epub ahead of print] https://doi.org/10.1002/jmv.25709
4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. [Epub ahead of print] https://doi.org/10.1056/NEJMoa2002032
5. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly. 2020;2(8):113–22.
6. Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med. 2011;37(1):77–85. https://doi.org/10.1007/s00134-010-2051-x
7. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, Mushtaq A. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129–32. https://doi.org/10.1093/jac/dkv085
8. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Defi nition. JAMA. 2012;307(23):2526–33. https://doi.org/10.1001/jama.2012.5669
9. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, BannerGoodspeed VM, Officer L, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med. 2016;193(1):52–9. https://doi.org/10.1164/rccm.201503-0584OC
10. Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):3. https://doi.org/10.1186/s13613-017-0350-x
11. Combes A, Brodie D, Bartlett R, Brochard L, Brower R, Conrad S, et al. Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am J Respir Crit Care Med. 2014;190(5):488–96. https://doi.org/10.1164/rccm.201404-0630CP
12. Schmidt GA, Girard TD, Kress JP, Morris PE, Ouellette DR, Alhazzani W, et al. Official executive summary of an American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Am J Respir Crit Care Med. 2017;195(1):115–9. https://doi.org/10.1164/rccm.201610-2076ST
13. Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915–36. https://doi.org/10.1086/677144
14. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. https://doi.org/10.1371/journal.pmed.0030343
15. Rochwerg B, Alhazzani W, Gibson A, Ribic CM, Sindi A, Heels-Ansdell D, et al. Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network metaanalysis. Intensive Care Med. 2015;41(9):1561–71. https://doi.org/10.1007/s00134-015-3794-1
16. Rochwerg B, Alhazzani W, Sindi A, Heels-Ansdell D, Thabane L, Fox-Robichaud A, et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med. 2014;161(5):347–55. https://doi.org/10.7326/M14-0178
17. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5):428–39. https://doi.org/10.1097/PCC.0000000000000350
18. Davis AL, Carcillo JA, Aneja RK, Deymann AJ, Lin JC, Nguyen TC, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2017;45(6):1061–93. https://doi.org/10.1097/CCM.0000000000002425
19.
20.
Review
For citations:
Romanov B.K. Coronavirus disease COVID-2019. Safety and Risk of Pharmacotherapy. 2020;8(1):3-8. (In Russ.) https://doi.org/10.30895/2312-7821-2020-8-1-3-8
Views:
9839
Email this article 